The IVth International Symposium on Neural Transplantation consisted of a total of 330 papers, including 236 submitted papers. Of the submitted papers, 27 were selected for oral presentation and 209 were chosen for poster presentation. In addition, there were 94 invited oral presentations. The total number of papers in the symposium series continues to increase, from 215 papers presented in Rochester in 1987 and the 233 papers presented in Cambridge in 1989, representing a remarkable continued increase in participation and expansion of the field. The overall quality of the material presented was outstanding, and there was a substantial participation of scientists from various fields related to neural transplantation, including studies of neurotrophins and other growth factors, CNS immunology, and brain development. The following report represents a selective discussion of papers which were presented at the meeting. The amount of material presented was vast, and no attempt has been made to be comprehensive. Thus it should be emphasized that many outstanding papers are not included in the present report. Apologies are extended to the numerous participants whose papers are not described herein. Citations are given to the abstracts (Restorative Neurology and Neuroscience, Volume 4, number 3, July, 1992) and extended abstracts (Journal of Neural Transplantation and Plasticity, Volume 3, number 4, Oct. Dec., 1992), and to other primary sources in some cases. Five abstracts of papers presented at the symposium, which arrived too late for publication, were printed in the meeting program. This summary report covers selected aspects of basic studies, CNS plasticity and development, growth factors, immunology, cell lines, glial cells, studies related to Parkinson’s disease and catecholaminergic cells, Huntington’s disease, cortical function, new models, and pain. Four additional brief summary reports which discuss the sessions on biomaterials and encapsulation, the visual system, new animal models, and spinal cord follow.

/pdf/neural-transplantation-a-report-on-the-ivth-international-18pjj69eqo.pdf

Neural Transplantation: A Report on the IVth International Symposium

Down’s syndrome (DS, trisomy 21) results from an extra copy of human chromosome 21. Included in the phenotype of this syndrome is the development of neurofibrillary tangles and neuritic plaques that are characteristic of Alzheimer’s disease (AD) (Wisniewski KE et al., Ann Neurol 1985; 17: 278-282). The hippocampus is an early and critical site of this pathology. Animal models would greatly aid the elucidation of processes underlying the neuropathology of DS and AD. Murine trisomy 16 is a proposed genetic model for DS owing to the homology between mouse chromosome 16 and human chromosome 21 (Epstein CJ, Trends Genet 1985; 1: 129-134). To determine whether the trisomy 16 mouse could be a useful model for AD, we investigated whether trisomy 16 brain tissue develops AD neurodegeneration and neuropathology. Because age is an important factor in the development of AD neurodegeneration and trisomy 16 mice do not survive past birth, neural tissue was maintained by transplantation so that the neurons might live long enough to express the AD phenotype. Trisomy 16 mice were produced by mating males doubly heterozygous for the Robertsonian translocations Rb(11.16)2H/Rb(16.17)32 Lub to C57B1/6 females. Hippocampal anlagen from embryonic day 15-17 fetal mice, trisomic for chromosome 16 or euploid litter-mates, was dissected free, cut into two or three pieces and taken up into a 10 /zl Hamilton syringe. A craniotomy was performed in host 6-8 week old female C57B1/6 mice and the tissue was injected stereotaxically into striatum or lateral ventricle. In some cases, hippocampal tissue was dissociated with trypsin prior to grafting (Fine A, Neurosci Lett 1991; 122: 4-8). Following up to fourteen months of survival in vivo, brains were fixed by perfusion with 4% paraformaldehyde, sectioned and the grafts were examined by standard histochemical techniques and by immunocytochemistry for senile plaques and neurofibrillary tangles of AD patients. Nissl-stained grafts appeared healthy with no areas of necrosis or degeneration. The grafts contained neuronal aggregates similar to the pyramidalor the granule-cell layers of the normal adult hippocampus. No obvious morphological difference was detected between trisomic and control transplants. No evidence of neuropathology was found in thioflavin Sor silver-stained sections. The monoclonal antibody Alz-50 (provided by Dr. P. Davies, Albert Einstein College of Medicine, and Dr. H. Ghanbari, Abbott Lab.), which recognizes the paired helical filaments characteristic of AD, did not stain trisomic or euploid grafts. However, frontal cortex from an AD patient, stained in parallel with the mouse sections, reacted strongly, thus indicating that the lack of staining in the mouse sections was not a failure of the immunohistochemical procedure. An antibody to/3-amyloid peptide (R1280, provided by Dr. I. Lieberberg, Athena Neurosciences) revealed no/3-amyloid accumulation in these grafts, whereas concurrent staining of AD frontal cortex demonstrated numerous plaques. We examined four trisomic en bloc grafts after one year of survival, and two grafts each after four, six and fourteen months using Alz-50 and R1280 antibodies; none showed AD-type immunoreactivity. Four dissociated cell trisomic grafts, after 18 months in vivo, did not stain with Alz-50. Further, antibodies against ubiquitin, 200 kDa subunit of neurofilament and tau, which stain neurofibrillary tangles, and antibodies

/pdf/examination-of-alzheimer-type-neurodegeneration-in-mouse-157mlwr5oy.pdf

S. I. Rapoport

Papers

Examination of Alzheimer-Type Neurodegeneration in Mouse Trisomy 16 Neurons Maintained by Transplantation